Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix
Accesswire
*INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE..
*INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE..
*Rainfactory co-founder assumes the role as sole Chief Executive Officer, completing a leadership transition that began in Q4..
XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndromeBreakthrough Therapy approval follows Priority..